wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q39667385-2DC243CC-2827-4389-99F0-BBBE960C1B98
Q39667385-2DC243CC-2827-4389-99F0-BBBE960C1B98
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39667385-2DC243CC-2827-4389-99F0-BBBE960C1B98
Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
P2860
Q39667385-2DC243CC-2827-4389-99F0-BBBE960C1B98
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39667385-2DC243CC-2827-4389-99F0-BBBE960C1B98
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d1393aa61642d557ddc57f74a7ca6968a8a433b1
P2860
Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada